ROR1-specific antibodies or efflux pump inhibitors can reverse chemotherapy resistance and tumor recurrence caused by ROR1-induced ATP-dependent drug efflux pump (ABCB1) expression in BCs (Fultang et al., 2020). The gene discussed is ROR1; the disease is neoplasm.